By clicking Accept you are verifying that you are a
US Healthcare Professional. This information is intended
for US Healthcare Professionals.


This site is intended for US Healthcare Professionals

Important Safety Information US Full Prescribing Information, including Boxed WARNING
Important Safety Information

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death compared to placebo (4.5% vs 2.6%, respectively). Although the causes of death were varied, most of the deaths appeared to be cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Abilify Maintena® (aripiprazole) is not approved for the treatment of patients with dementia-related psychosis. Important Safety Information Continued Below


Abilify Maintena® (aripiprazole) significantly
delayed the time to relapse* vs placebo

*Abilify Maintena significantly delayed the time to relapse vs placebo (P<0.0001) in a Phase III, 52-week,
double-blind, randomized-withdrawal clinical trial; Abilify Maintena (n=269) vs placebo (n=134).